I. Boere, B. Pothuri, Olena Sukhina, T. Myers, Valentina Tuninetti, A. A. Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, L. Gilbert, Michael J Callahan, L. Willmott, Michael A Gold, M. Powell, C. Mccourt, Veena Vincent, Veronika Simang, M. Mirza, N. Cloven
{"title":"633 在ENGOT-EN6-NSGO/GOG-3031/RUBY试验中,与化疗相比,多司他啶联合化疗治疗原发性晚期或复发性子宫内膜癌患者的患者报告结果恶化时间","authors":"I. Boere, B. Pothuri, Olena Sukhina, T. Myers, Valentina Tuninetti, A. A. Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, L. Gilbert, Michael J Callahan, L. Willmott, Michael A Gold, M. Powell, C. Mccourt, Veena Vincent, Veronika Simang, M. Mirza, N. Cloven","doi":"10.1136/ijgc-2024-esgo.33","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"56 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial\",\"authors\":\"I. Boere, B. Pothuri, Olena Sukhina, T. Myers, Valentina Tuninetti, A. A. Secord, Florian Heitz, Paul Nowicki, Annika Auranen, Nicole Nevadunsky, L. Gilbert, Michael J Callahan, L. Willmott, Michael A Gold, M. Powell, C. Mccourt, Veena Vincent, Veronika Simang, M. Mirza, N. Cloven\",\"doi\":\"10.1136/ijgc-2024-esgo.33\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"56 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.33\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
633 Time to deterioration of patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial